EW - Edwards Lifesciences Corporation
| Previous Close | 238.58 |
| Open | 239.81 |
| Bid | 236.37 x 1200 |
| Ask | 240.00 x 1300 |
| Day's Range | 238.02 - 239.97 |
| 52 Week Range | 163.08 - 247.64 |
| Volume | 1,237,365 |
| Avg. Volume | 1,179,953 |
| Market Cap | 49.773B |
| Beta (5Y Monthly) | 0.77 |
| PE Ratio (TTM) | 65.52 |
| EPS (TTM) | 3.64 |
| Earnings Date | Jan. 29, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 250.74 |
- Zacks
Edwards Lifesciences (EW) Stock Sinks As Market Gains: What You Should Know
Edwards Lifesciences (EW) closed the most recent trading day at $231.46, moving -0.67% from the previous trading session.
- Simply Wall St.
Is Edwards Lifesciences Corporation (NYSE:EW) Excessively Paying Its CEO?
In 2000 Mike Mussallem was appointed CEO of Edwards Lifesciences Corporation (NYSE:EW). This analysis aims first to...
- Zacks
Edwards Lifesciences (EW) Stock Moves -0.5%: What You Should Know
In the latest trading session, Edwards Lifesciences (EW) closed at $234.61, marking a -0.5% move from the previous day.
- Zacks
Edwards (EW) Rides on Innovation Despite Regulatory Issues
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
- Zacks
Top Stock Picks for the Week of Dec 23, 2019
Tracey Ryniec takes a look at two Zacks Rank 1 (Strong Buy) stocks.
- Zacks
Zacks Market Edge Highlights: Edwards Lifesciences, Sony, Alibaba, State Street and Exxon
Zacks Market Edge Highlights: Edwards Lifesciences, Sony, Alibaba, State Street and Exxon
- Zacks
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
The Zacks Analyst Blog Highlights: Uber, AES, CIRCOR International, Edwards Lifesciences and Zynerba Pharmaceuticals
- Zacks
Investing Outlook for 2020: Recession or Not?
Some stock market bears have been waiting for a US recession for four years. Is 2020 the year they will finally be right or will they have to throw in the towel and join the bull's party?
- Zacks
Uber Is Formally into the Staffing Business
Uber Works makes Uber more like the technology platform it claims to be and less the ride-hailing service that we recognize it as.
- Zacks
Edwards Lifesciences (EW) Upgraded to Strong Buy: Here's Why
Edwards Lifesciences (EW) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks
Edwards Lifesciences (EW) Dips More Than Broader Markets: What You Should Know
Edwards Lifesciences (EW) closed at $235.63 in the latest trading session, marking a -0.96% move from the prior day.
- Zacks
Here's Why You Should Hold on to Allscripts Stock for Now
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
- Zacks
Here's Why You Should Bet on Integer Holdings Stock Now
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
- Zacks
Here's Why You Should Invest in Cardinal Health Stock Now
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
- Zacks
NextGen Healthcare Boosts Patient Care With CHC Strategies
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
- Zacks
Here's Why You Should Retain NextGen Healthcare for Now
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
- Zacks
Edwards Lifesciences (EW) Plans Strong Long-Term TAVR Growth
Within TAVR, Edwards (EW) expects global TAVR opportunity to exceed $7 billion by 2024.
- Zacks
Here's Why You Should Hold on to Cerner (CERN) Stock Now
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.
- Zacks
NuVasive (NUVA) Hits 52-Week High, Can the Run Continue?
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
Here's Why You Should Retain Nevro (NVRO) Stock for Now
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
- Zacks
Cooper Companies (COO) Q4 Earnings Beat, Revenues Rise Y/Y
Cooper (COO) gains from solid segmental contributions in fiscal fourth quarter.
